lining banking services are available in the following countries: Singapore, Hong Kong, India, Indonesia, Malaysia, the Philippines, Bangladesh, Myanmar and Vietnam. Non-invasive Newborn Metabolic Screening Newborn metabolic screening screens for inborn errors of metabolism from urine samples that can impact the health of newborns. Metabolic disorders are usually not apparent at the time of birth. If left undiagnosed and untreated, the baby can suffer from neurological impairment and physical deformities. Cordlife has already launched this newborn metabolic screening test (Metascreen) in the following countries: Hong Kong (through HealthBaby and Cordlife Hong Kong), Philippines, Indonesia and Malaysia. Non-invasive Prenatal Testing Non-invasive prenatal testing ("NIPT") is a relatively new and highly accurate prenatal screening test that analyses foetal DNA in the mother's blood for potential foetal chromosomal abnormalities, including Down syndrome, Edwards syndrome and Patau syndrome. The test can be performed as early as 10th week of gestation through a simple and safe blood draw. NIPT has an accuracy rate of over 99%, much higher than conventional maternal marker-based prenatal tests. Through strategic partnerships with their third-party service providers, Cordlife is offering this services in Singapore, India, Indonesia and the Philippines. Newborn Genetic Screening A non-invasive screening for chromosomal abnormalities and gene variants connected to more than 120 genetic disorders in babies using cord blood. Paediatric Vision Screening Cordlife offers paediatric vision screening marketed under the brand Eyescreen, a marketing trademark of the Group's wholly owned subsidiary Cordlife Technologies Pte Ltd. Eyescreen is a safe and non-invasive paediatric vision screening service for children aged between six months and six years old. The test detects up to 11 eye conditions such as strabismus (crossed eyes) and amblyopia (lazy eye) using a device with photoscreening technology. Available in Singapore. International operations Singapore Cordlife Singapore is the country’s first private cord blood bank and the corporate headquarters of the Group. Situated at A’Posh Bizhub, Yishun, Cordlife Singapore’s fully owned 23,000 square feet processing and storage facility has a storage capacity of up to 650,000 cord blood units. Since 2005, Cordlife Singapore has been accredited by AABB. To date, Cordlife Singapore has successfully released 14 cord blood units to its clients. In May 2013, Cordlife Technologies Pte Ltd (“CTPL”), a wholly owned subsidiary of the Group, launched cord lining banking service in Singapore. In December 2015, their facility was successfully accredited by FACT-Netcord, a gold standard for cord blood banking. This places them amongst only six